Literature DB >> 18504504

Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats.

Shan-Shan Xing1, Hong-Wei Tan, Xiu-Ping Bi, Ming Zhong, Yun Zhang, Wei Zhang.   

Abstract

Metabolic syndrome is associated with accelerated macrovascular and microvascular coronary disease, cardiomyopathy, and elevated inflammatory status. To determine whether metabolic syndrome-associated elevation of the inflammatory cytokine interleukin-18 (IL-18) in serum and cardiac tissue, and its potential sequelae could be attenuated pharmacologically, we studied fructose-fed rats. The fructose-fed rats exhibited increases in systolic blood pressure (SBP), body weight, heart weight, left ventricular weight, and blood insulin. Serum IL-18 levels in these rats were also elevated significantly. These changes were significantly different compared to those in control rats. Perivascular fibrosis around coronary arterioles was evident in the fructose-fed rats, accompanied by a paralleled increase in IL-18 by immunohistochemical analysis and real time polymerase chain reaction. Felodipine attenuated the increased levels in serum IL-18 and cardiac IL-18 mRNA as well as coronary perivascular fibrosis. Thus, augmented IL-18 in serum and cardiac tissue in metabolic syndrome may contribute to the coronary perivascular fibrosis; felodipine administration can attenuate the inflammatory and fibrosis process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18504504      PMCID: PMC2394497          DOI: 10.2119/2008-00024.Xing

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  48 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Cytokine milieu tends toward inflammation in type 2 diabetes.

Authors:  Katherine Esposito; Francesco Nappo; Francesco Giugliano; Carmen Di Palo; Myriam Ciotola; Michelangela Barbieri; Giuseppe Paolisso; Dario Giugliano
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

3.  Differentiation between obesity and insulin resistance in the association with C-reactive protein.

Authors:  Tracey McLaughlin; Fahim Abbasi; Cindy Lamendola; Lynn Liang; Gerald Reaven; Patricia Schaaf; Peter Reaven
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

4.  Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.

Authors:  Mariame El Messal; Jean-Louis Beaudeux; Anas Drissi; Philippe Giral; Rachid Chater; Eric Bruckert; Ahmed Adlouni; M John Chapman
Journal:  Clin Chim Acta       Date:  2005-11-08       Impact factor: 3.786

5.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

6.  Nilvadipine inhibits nuclear factor-kappaB-dependent transcription in hepatic cells.

Authors:  Yasumasa Iwasaki; Masato Asai; Masanori Yoshida; Takeshi Nigawara; Machiko Kambayashi; Yutaka Oiso; Nobuo Nakashima
Journal:  Clin Chim Acta       Date:  2004-12       Impact factor: 3.786

7.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study.

Authors:  M Fröhlich; A Imhof; G Berg; W L Hutchinson; M B Pepys; H Boeing; R Muche; H Brenner; W Koenig
Journal:  Diabetes Care       Date:  2000-12       Impact factor: 19.112

8.  Weight loss reduces interleukin-18 levels in obese women.

Authors:  Katherine Esposito; Alessandro Pontillo; Myriam Ciotola; Carmen Di Palo; Elisa Grella; Gianfranco Nicoletti; Dario Giugliano
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

9.  Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity.

Authors:  Héctor F Escobar-Morreale; José I Botella-Carretero; Gemma Villuendas; José Sancho; José L San Millán
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells.

Authors:  Y Ding; N D Vaziri
Journal:  Hypertension       Date:  1998-10       Impact factor: 10.190

View more
  6 in total

1.  Overexpression of interleukin-18 aggravates cardiac fibrosis and diastolic dysfunction in fructose-fed rats.

Authors:  Shan-Shan Xing; Xiu-Ping Bi; Hong-Wei Tan; Yun Zhang; Qi-Chong Xing; Wei Zhang
Journal:  Mol Med       Date:  2010-07-12       Impact factor: 6.354

2.  Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs).

Authors:  Hoda E Mohamad; Mervat E Askar; Mohamed M Hafez
Journal:  Diabetol Metab Syndr       Date:  2011-03-30       Impact factor: 3.320

3.  The Role of the NLRP3 Inflammasome in Fibrosis.

Authors:  Carol M Artlett
Journal:  Open Rheumatol J       Date:  2012-06-15

4.  Effects of Postconditioning with Fructose on Arrhythmias and the Size of Infarct Caused by Global Ischemia and Reperfusion in Isolated Rat Heart.

Authors:  Jila Haghi; Tahereh Eteraf-Oskouei; Moslem Najafi
Journal:  Adv Pharm Bull       Date:  2018-03-18

5.  Effect of Rosmarinic Acid and Sinapic Acid on Oxidative Stress Parameters in the Cardiac Tissue and Serum of Type 2 Diabetic Female Rats.

Authors:  Maria Zych; Weronika Wojnar; Sławomir Borymski; Katarzyna Szałabska; Piotr Bramora; Ilona Kaczmarczyk-Sedlak
Journal:  Antioxidants (Basel)       Date:  2019-11-22

6.  Fructose Beverage Consumption Induces a Metabolic Syndrome Phenotype in the Rat: A Systematic Review and Meta-Analysis.

Authors:  Carla R Toop; Sheridan Gentili
Journal:  Nutrients       Date:  2016-09-20       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.